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Abstract 
This study investigated the effects of acute branched-chain amino acid (BCAA) 
supplementation on recovery from exercise-induced muscle damage, among experienced 
resistance-trained athletes. In a double-blind matched-pairs design, 16 resistance-trained 
participants, routinely performing hypertrophy training, were randomly assigned to a BCAA 
(n = 8) or placebo (n = 8) group. The BCAAs were administered at a dosage of 0.087 g/kg 
body mass, with a 2:1:1 ratio of leucine, isoleucine and valine. The participants performed 6 
sets of 10 full-squats at 70 % 1RM to induce muscle damage. All participants were diet-
controlled across the study. Creatine kinase (CK), peak isometric knee-extensor force, 
perceived muscle soreness and counter-movement jump (CMJ) height were measured 
immediately before (baseline), 1-h, 24-h and 48-h post-exercise. There were large to very 
large time effects for all measurements between baseline and 24-48 h. Between-group 
comparisons, expressed as a percentage of baseline, revealed differences in isometric strength 
at 24-h (Placebo ~87% c.f. BCAA ~92 %; moderate, likely), CMJ at 24-h (Placebo ~93 % c.f. 
BCAA ~96 %; small, likely) and muscle soreness at both 24-h (Placebo ~685 % c.f. BCAA 
~531 %; small, likely) and 48-h (Placebo ~468 % c.f. BCAA ~350 %; small, likely). Acute 
supplementation of BCAAs (0.087 g/kg) increased the rate of recovery in isometric strength, 
CMJ height and perceived muscle soreness compared to placebo after a hypertrophy-based 
training session among diet-controlled, resistance-trained athletes. These findings question 
the need for longer BCAA loading phases and highlight the importance of dietary control in 
studies of this type. 
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Introduction  
Habitual resistance exercise can be used to increase muscle strength and compensatory 
growth known as ‘hypertrophy’ (Goldberg et al., 1975). Whilst the optimal training regime to 
increase muscle mass has not yet been established (Carpinelli et al., 2004; Philips, 2009; 
Mitchell et al., 2012), it is typical for athletes to perform between 3-5 repeated bouts of 
resistance exercise to fatigue per micro-cycle (ACSM, 2009). These sessions commonly 
comprise 2-6 sets of resistance exercise, targeting major muscle groups, at intensities ranging 
from 6-12 maximum repetitions (RM) to failure (ACSM, 2009). Performing resistance 
exercise in this manner is partly intended to create mechanical tension, thus disturbing the 
integrity of skeletal muscle (Schoenfeld, 2010; 2012). It has been postulated that the 
exercise–induced muscle damage (EIMD) caused by resistance exercise initiates a cascade of 
intracellular signalling processes that upregulate the synthesis of muscle proteins and increase 
cell size (Schoenfeld, 2012). In the days (24-72 hours) after performing this type of exercise, 
participants are likely to experience symptoms of EIMD, such as delayed-onset muscle 
soreness (DOMS), decreased force production and leakage of intramuscular proteins into 
circulation (i.e. creatine kinase; CK) (Sorichter et al., 1999).  
 
Recovery from EIMD is an important part of the adaptive process, which can take up to 72 
hours (Barnett, 2006; Howatson and van Someren, 2008; Nedelec et al., 2013). Given the 
demands of frequent resistance training, full and rapid recovery between bouts of exercise is 
desirable. Interventions that help to attenuate the effects of muscle damage would, therefore, 
be beneficial to the athlete by reducing the decline in physical function, thus permitting 
greater engagement with training in the days following exercise (Cheung et al., 2003; Proske 
and Morgan, 2001; Howatson and van Someren, 2008). Furthermore, interventions that lower 
  
the perception of fatigue and DOMS or maintain the intracellular anabolic environment 
would also support the training or adaptation process. Branched-chain amino acids (BCAAs), 
in particular leucine, are commonly used as prophylactic interventions to attenuate symptoms 
of muscle damage (da Luz et al., 2011). Leucine supplementation has also been suggested to 
suppress muscle proteolysis (Zanchi et al., 2008) and reduce protein oxidation (Shimomura et 
al., 2009) after muscle-damaging exercise, thus maintaining the integrity of the sarcolemma. 
Indeed, the appearance of indirect markers of muscle damage, such as CK, have been reduced 
by both short- (Nosaka et al., 2006; Kirby et al., 2012; Shimomura et al., 2010) and long-term 
amino acid supplementation (loading) periods (Coombes and McNaughton, 2000; Howatson 
et al., 2012; Sharp and Pearson, 2010). The attenuation in CK efflux after BCAA 
supplementation has been linked to a reduction in secondary damage, caused by the 
inflammatory response (Howatson and van Someren, 2008). The dampening of acute 
inflammatory responses might also explain the commonly-reported reductions in DOMS 
following mixed amino acid (Nosaka et al., 2006), isolated leucine (Kirby et al., 2012) or 
mixed BCAA supplementation (Shimomura et al., 2010; Howatson et al., 2012). Reductions 
in DOMS and cell damage might, in turn, explain the accelerated recovery of muscle function 
after leucine or mixed BCAA supplementation (Kirby et al., 2012; Howatson et al., 2012). 
 
There are numerous inconsistencies and limitations among previous studies that question the 
assumed recovery properties of BCAAs. Firstly, only one study has used participants with a 
recent resistance-training history (Howatson et al., 2012). Whilst it is suggested to omit 
resistance-trained participants from muscle-damage studies because of the repeated-bout 
effect (RBE) (McHugh, 2003), several studies have found that protective adaptation is absent 
amongst resistance-trained men and well-trained athletes (Bloomer et al., 2006; Falvo et al., 
2007; Falvo et al., 2009). Indeed, if the RBE is absent amongst this population, it increases 
  
the efficacy of BCAA supplementation among athletes who are training regularly and, most 
likely, require strategies to hasten recovery between training sessions. Furthermore, there has 
been no study to assess the efficacy of BCAA supplementation among resistance-trained 
athletes following a bout of hypertrophy-type exercise, opposed to eccentrically-biased 
exercise (i.e. 100 drop-jumps; Howatson et al., 2012). This is important, given that a recent 
study has suggested that that the efficacy of BCAA supplementation as a recovery agent is 
dependent on the degree of muscle damage, and it is likely to be more effective after 
‘moderate’ muscle damage (Fouré et al., 2016), such as that induced by performing non-
ballistic concentric/eccentric lifting patterns, realistic of hypertrophy training programmes. 
Additionally, the evidence to support the optimal timing of BCAA supplementation for 
recovery from EIMD is equivocal, with research showing positive effects after 30 min of pre-
exercise supplementation (Howatson et al., 2012; Kirby et al., 2012), compared to others who 
have supplemented for up to three weeks (Sharp and Pearson, 2010). That 30 min of pre-
exercise BCAA is sufficient to reduce markers of EIMD is consistent with its 1-2 hour peak 
bioavailability following ingestion (Dickinson et al., 2014; Fouré et al., 2016). This also 
indicates that longer supplementation periods might be unnecessary to promote recovery 
from muscle damage, whilst also incurring a greater financial cost for athletes. Lastly, only 
one study has monitored the dietary intake (Jackman et al., 2010) of participants, meaning 
that the amount of protein and other macronutrients ingested is often unaccounted for. This is 
important since the energy content and protein included in a diet might optimise the recovery 
of subjects, independent of the BCAA supplement.  
 
Based on the above reasoning, the aim of this study was to investigate the effects of acute 
body-mass dependent BCAA supplementation on recovery from specific EIMD, among 
athletes who take part in long-term training programmes, designed to induce muscle 
  
hypertrophy. It was hypothesized that the BCAA supplementation would attenuate the 
reductions in muscle function and increases in DOMS, as well as lowering the biochemical 
responses, compared to the placebo group.  
 
Methods 
Participants 
Fourteen males (mean ± SD age 21.8 ± 1.6 years, stature 183.3 ± 6.2 cm, body mass 95.1 ± 
11.8 kg, 1RM Squat 175 ± 32 kg) and two females (mean ± SD age 22 ± 1 years, stature 
161.5 ± 1.5 cm, body mass 57 ± 3 kg, 1 RM squat 68.5 ± 2.5 kg) consented to take part in this 
study. All participants were experienced resistance-trained athletes, with a minimum of three 
years training history, who had consistently used a full-squat technique in their own 
hypertrophy programmes. To be included in this study, the participants had to be injury-free 
and train at least three times per week using resistance exercises that fall within the typical 
hypertrophy training sets and repetition ranges described in the literature (ACSM, 2009), with 
at least three years of training history. The BCAA group had 3.9 ± 0.7 years of resistance 
training experience, while the placebo group had 4.3 ± 1.6 years. Participants were initially 
screened for any recent injuries or movement compensations that may cause pain or 
discomfort when squatting or factors influencing their ability to perform the required 
moments. Ethical approval was granted for this study by the Institutional ethics committee 
(SMEC_2016-17_001).  
 
Design 
Two weeks prior to testing, participants were told to cease any use of nutritional supplements, 
additional to their normal diet, such as protein supplements, creatine and amino acids. The 
participants were advised to avoid any drugs with anti-inflammatory properties and not to use 
  
compression garments or seek or therapeutic intervention, such as hydrotherapy treatments or 
forms of massage. They were also provided with a diet plan to follow from 48-h before the 
study until their final testing day. The intended energy content of their diet plans was based 
on published approaches (Alfonzo-Gonzales et al., 2004) and provided three options of 
breakfast, lunch, dinner and snacks. For consistency, the meal options comprised a 
macronutrient composition of 50% carbohydrate, 15% protein (of similar amino acid content) 
and 35% fat. Caloric intake was monitored throughout the study using ‘My Fitness Pal’ 
(MyFitnessPal Inc, Austin, TX). The reported caloric intake of the participants during the 
study (males and females) was 2486 ± 412 kcal/day and 2667 ± 449 kcal/day in the BCAA 
and placebo groups, respectively. The actual reported macronutrient compliance during the 
study was: 46 ± 9 % carbohydrates, 15 ± 3 % protein and 39 ± 8 % fat. The participants 
visited the laboratory at the same time of day (1000-1100) on four separate days, 
approximately 1-2-h after breakfast. During visit 1, the participants familiarized with the 
testing procedures, were tested for their 1 RM and weighed for subsequent calculation of the 
BCAA supplement. The participants were given specific instructions for how to perform a 
back squat, including tempo and joint positioning, as this would be the mode of muscle-
damage during the study. Visit 1 was carried out 72-h before the next visit (visit 2) and no 
other exercise was performed in between. Familiarization was deemed to be sufficient after 
one visit as the participants were consistent in their performance on all tests and indicated 
that they were comfortable in performing them. After visit 1, the participants were assigned 
to one of the two conditions (BCAA supplement or placebo) in a double-blind, matched-pairs 
design. The participants were matched on body mass, sex and 1 RM strength. The 
supplements (placebo or BCAA) were consumed 30-min before and after the muscle damage 
protocol. Over the following 48-h, the supplements were provided 30-min before and after re-
testing. The supplements were prepared by an independent laboratory technician, who was 
  
also responsible for the random allocation of participants to each group. The randomisation 
was carried out by assigning each participant a number and using publicly available software 
to allocate their group (http://www.randomization.com/). On visit 2, the participants had 
capillary blood samples drawn from the finger for the measurement of baseline creatine 
kinase (CK) and then performed a battery of tests in the following order: perceived soreness, 
lower-limb isometric strength and countermovement jumping. After the baseline testing, the 
participants were supervised through the muscle-damage protocol. One hour after the damage 
protocol, the same measurements were taken. Visits 3 and 4 followed 24-h and 48-h, 
respectively, after the muscle damage protocol, where the same battery of tests were 
performed.  
 
Procedure 
Knee-extensor isometric strength  
To test the maximal isometric strength of the knee-extensor muscles, each participant sat on a 
custom made, adaptable strength chair, with their back and knees fully supported. Their knee 
was firmly fixed at 100˚ and their hips at 110˚, which was verified using a goniometer. Their 
right leg was firmly strapped to the chair across the mid-thigh, whilst their ankle 
(immediately above malleoli) was fixed to a strain gauge (Interface SSM-AJ-500 Force 
Transducer; Interface, Scottsdale, AZ; 0.05% maximum error), sampling at 1000 Hz. The 
strain gauge recorded force as alteration in voltage. Calibration of the strain gauge with a 
known mass demonstrated the relationship between voltage and Newtons as linear, allowing 
determination of a regression formula to convert voltage to Newtons. A second calibration 
was performed with the same weights at the completion of testing, producing an ICC of 0.99. 
The strain gauge was attached to the participant using a high tension belt. The chair set-up 
was replicated for each participant in subsequent trials. Their upper-body was also tightly 
  
fitted to the chair with two straps across each shoulder, which they were instructed to grip 
with their hands throughout the testing. A command of ‘3-2-1-GO’ was given, after which the 
participants performed a maximal isometric knee extension for 5-s. Non-specific verbal 
encouragement was provided to the participants for motivation. Participants performed three 
maximal tests, separated by 2-min. A maximal voluntary contraction (MVC) was determined 
as the highest of three values. If the peak force (N) produced by participants systematically 
increased across the three tests, a fourth test was conducted. The reliability of this procedure 
was 2% (coefficient of variation; CV). 
 
Counter-movement jumping (CMJ) 
Participants performed a CMJ on a jump mat (Probiotics Inc, Huntsville, AL, USA) by 
standing with their feet at shoulder width, hands on hips and descending to ~90˚ before 
propelling themselves vertically to the highest possible height, keeping their legs fully 
extended. Standardised non-specific motivation and cues were provided to facilitate 
performance. The participants performed three jumps, separated by 2-min and the highest 
jump height (cm) was recorded. If the values systematically increased across the three tests, a 
fourth test was conducted. The test re-test reliability of this procedure was 1.2% (CV).  
 
Blood sampling and analysis 
The index fingertip of the subject was cleaned using a sterile alcohol swab and allowed to 
dry. Capillary blood was drawn from the finger and a sample of whole blood (30 μL) was 
collected into a heparinised capillary tube. The whole blood was centrifuged at 3000 rpm 
(4°C) for 5 min, and the resultant plasma was removed and stored at -80°C until subsequent 
analysis. Plasma CK was measured using a chemistry analyser (Rx Monza, Randox 
Laboratories Ltd., Crumlin, Antrim, UK). The intra-sample CV of the analyser is < 4% CV at 
  
high and low concentrations and the expected baseline sample range is 37-2755 IU/L for CK, 
according to manufacturer’s guidelines. To eliminate inter-assay variance, all samples were 
analysed in the same assay run 
 
Perceived soreness 
The participants were asked to rate their perceived muscle soreness in the lower-limbs from 
0-10 on a 200 mm Visual Analogue Scale (VAS). The numbers were concealed from the 
participant on the reverse of the scale, whilst the verbal anchors of no muscle soreness (~0 on 
reverse), soreness upon movement (~5 reverse) and too sore to move (~10 reverse) were 
observed from the front of the scale. To do this, the participants performed a 5-s isometric 
squat, with their ankles, knees and hips at 90˚ and, after 5-s, moved a sliding scale to the 
number which they perceived to correspond to their level of soreness (Howatson et al., 2012).  
 
Supplementation 
Each participant was supplemented with either a placebo or a BCAA beverage, both of which 
contained 0.25 g/kg body mass of dextrose dissolved into 300 ml of water, thus ensuring 
drinks were indistinguishable in taste. The BCAA drinks were supplemented at a dosage of 
0.087 g/kg body mass (Børsheim et al., 2002), consisting of leucine, isoleucine, and valine in 
a 2:1:1 ratio (Myprotein, Cheshire, UK). This dosage of AA has been shown to promote 
recovery from resistance exercise (Børsheim et al., 2002) and the ratio of leucine, isoleucine 
and valine was pre-determined by the manufacturer. Drinks were consumed 30-min before 
and immediately after the muscle damage protocol (Jackman et al., 2010). Over the following 
48-h, the supplements were provided 30-min before and immediately after re-testing. On the 
final day, the supplement was taken with breakfast and 30-min before testing to provide two 
doses.   
  
 
Muscle-damage protocol 
A standardised warm-up was performed on the day, comprising walking, dynamic stretching 
and squatting up to 30% of the final load. The participants then performed back squats at an 
intensity of 70% of 1 RM for 10 repetitions across 6 sets (ACSM, 2009). Two minutes rest 
was given between sets, where participants remained standing and were free to walk around a 
10 m x 10 m area. To replicate an optimal hypertrophy session, the participants were told to 
perform all repetitions as per their familiarisation, with an eccentric phase of 3-s, followed by 
a moderate 2-3 s concentric phase (Schoenfeld, 2010). If a set dropped below 8 repetitions, or 
the investigator judged the quality of technique to regress, then the weight was decreased by 
10% until the desired repetition range or lifting form was achieved. 
 
Statistical analyses 
Based on best-practice recommendations for research in sports nutrition (See Burke, 2008), 
effect sizes (ES) and magnitude-based inferences (MBIs) were used to identify mechanistic 
differences in the dependent variables between the two experimental conditions (placebo or 
BCAA). All of the dependent variables were expressed as change relative to baseline. Effect 
sizes were defined as; trivial = 0.2; small = 0.21–0.6; moderate = 0.61–1.2; large = 1.21–
1.99; very large > 2.0 (Batterham and Hopkins, 2006). Raw data were log-transformed to 
account for non-uniformity of effects. Threshold probabilities for substantial effects based on 
the 90% confidence limits were: <0.5% most unlikely, 0.5–5% very unlikely, 5–25% 
unlikely, 25–75% possibly, 75–95% likely, 95–99.5% very likely, 99.5% most likely. 
Thresholds for the magnitude of the observed change in the dependent variables were 
determined as the within-participant standard deviation × 0.2 (small) 0.6 (moderate) and 1.2 
(large). Effects with confidence limits across a likely small positive or negative change were 
  
classified as unclear (Hopkins et al., 2009). The uncertainty of effects was based on 90% 
confidence limits for all variables. A custom spreadsheet was used to perform all of the 
calculations (http://www.sportsci.org/.). 
 
Results 
There were trivial differences between BCAA and placebo groups for the total energy intake 
(2486 ± 412 kcal/day cf. 2667 ± 449 kcal/day; trivial, unlikely), carbohydrate (1157 ± 354 
kcal/day cf. 1230 ± 300 kcal/day; trivial, unlikely), fat (980 ± 283 kcal/day cf. 1049 ± 275 
kcal/day; trivial, unlikely) and protein energy intake (378 ± 79 kcal/day cf. 394 ± 101 
kcal/day; trivial, unlikely). 
 
Changes in isometric strength (% baseline) are presented in Figure 1 (mean ± SD). There 
were large reductions in isometric strength between baseline and post-exercise for the BCAA 
group (1031 ± 273 N cf. 976 ± 238 N, respectively most likely ↓), whilst the placebo group 
showed very large changes (899 ± 248 N cf. 734 ± 186 N, respectively; most likely ↓). By 24-
h post-testing, the reduction in strength remained very large for the placebo group (most 
likely ↓) and large for the BCAA group (most likely ↓), which were subsequently reduced to 
moderate, unclear changes among the placebo and BCAA conditions at 48-h. Both groups 
did not return to baseline strength levels during the study. Pairwise between-group tests 
revealed a greater reduction in isometric strength at 24-h in the placebo group compared to 
the BCAA group (moderate, likely ↓), indicating a delayed recovery of muscle function. 
 
*******Figure 1 near here******* 
 
  
Changes in CK concentration (% baseline) are presented in Figure 2 (mean ± SD). There 
were moderate increases in CK between baseline and post-exercise for the BCAA group (339 
± 77 IU/L cf. 783 ± 407 IU/L, respectively; very likely ↑), whilst there were small, unclear 
increases in the placebo group (357 ± 121 IU/L cf. 538 ± 235 IU/L, respectively ). By 24-h 
post-testing, the increase in CK was large and most likely for both groups, which remained 
large, and most likely between baseline and 48-h. Both groups did not return to baseline CK 
levels during the study. Pairwise between-group tests revealed large, possible increases in 
CK concentration at 24-h and 48-h in the BCAA group compared to the placebo group. 
 
*******Figure 2 near here******* 
 
Changes in CMJ height (% baseline) are presented in Figure 3 (mean ± SD). There were 
moderate, very likely reductions in CMJ height between baseline and post-exercise for the 
both groups (BCAA = 56.3 ± 6.9 cm cf. 54.6 ± 8.2 cm; Placebo = 55.4 ± 5.4 cm cf. 52.8 ± 6.2 
cm). By 24-h post-testing, the reduction in CMJ height was very large and most likely for 
both groups, which improved to a trivial, and unclear for both groups between baseline and 
48-h, indicating a return to baseline. Pairwise between-group tests revealed small, likely 
reductions in CMJ height at post-exercise and 24-h in the placebo group compared to the 
BCAA group. 
 
*******Figure 3 near here******* 
 
Changes in perceived muscle soreness (% baseline) are presented in Figure 4 (mean ± SD). 
There were large, most likely increases in perceived muscle soreness between baseline and 
post-exercise for the both groups (BCAA = 1.6 ± 0.9 AI cf. 8.6 ± 3.4 AI; Placebo = 1.8 ± 8.6 
  
AI cf. 8.6 ± 4.4 AI). By 24-h post-testing, the increase in perceived muscle soreness remained 
large and most likely for both groups, which improved to a trivial, and unclear between 
baseline and 48-h, indicating a return to baseline. Pairwise between-group tests revealed 
small, likely increases in perceived muscle soreness at 24-h and 48-h in the placebo group 
compared to the BCAA group. 
 
 
*******Figure 4 near here******** 
 
 
Discussion  
We investigated the effects of BCAA supplementation on recovery from muscle damage after 
a hypertrophy-based protocol, among participants regularly taking part in this form of 
exercise. All of the participants in this study exhibited indirect signs of exercise-induced 
muscle damage, with both the placebo and BCAA groups declining in strength and CMJ 
height and increasing DOMS and CK concentration across the 48-h recovery period. 
However, as hypothesised, the primary finding of this study was that a BCAA supplement of 
0.087 g/kg body mass was sufficient to reduce the effects of a hypertrophy-based training 
session on isometric strength, CMJ height and DOMS compared to placebo. The differences 
between groups were predominantly noted at the 24-48-h period, whereby the BCAA group 
showed differences (small to large) in strength, CMJ and DOMS compared to placebo 
(Figures 1-4), indicating faster recovery towards baseline values. That baseline values of 
strength or CMJ height were not re-established after 48-h was not unexpected as other studies 
have shown that muscle function and other performance measures do not return to baseline 
72-h to 96-h after muscle damage when BCAAs are orally administered (Jackman et al., 
  
2010; Howatson et al., 2012; Kirby et al., 2012). Most importantly, our findings support the 
suggestion that BCAA supplementation can increase the rate of recovery in muscle function 
among well-trained habitual weight-lifters, following a muscle damage protocol that 
mimicked a typical hypertrophy training session.  
 
Similar findings have been reported previously, where a comparable dosage of a BCAA 
supplement, administered across a 7-day loading period, accelerated the recovery of muscle 
function and DOMS (Howatson et al., 2012). Kirby et al. (2012) also reported an 
improvements in recovery of isometric strength, but not squat jump height, after muscle 
damage using a short-term (beginning 30-min prior to exercise) leucine supplementation 
regime, similar to the current study. On this basis, Kirby and co-authors questioned the 
usefulness of leucine as a recovery agent if its effects do not transfer to ballistic tasks. Indeed, 
others have reported similar findings, with no change in vertical jump height between placebo 
and BCAA groups after muscle damage (Howatson et al., 2012). In disagreement with these 
studies, we found that CMJ height was recovered faster in the BCAA group compared to 
placebo at 24-h post-damage. The use of a standard CMJ test, opposed to a static jump (Kirby 
et al., 2012), might partly explain this difference as it is known that movements involving the 
stretch-shortening cycle (SSC) can be effected by muscle damage, partly owing to structural 
changes in non-contractile elements and an associated loss of muscle-tendon stiffness (Komi, 
2000). In vitro studies have shown that leucine administration can promote the restoration of 
damaged connective tissue in rat skeletal muscle (Perieira et al., 2014), which is responsible 
for the transfer of energy between the muscle and tendon structures (Turrina et al., 2013). 
Therefore, it is feasible that the repair of damaged connective tissue was facilitated by BCAA 
supplementation, thus supporting energy transfer during SSC movements. There are other 
mechanisms, such as impairment of reflex-sensitivity (Komi, 2000) that might explain the 
  
poorer CMJ performance post-muscle damage. The lowered DOMS after BCAA 
supplementation is likely to have caused less neural inhibition, thus enabling improved reflex 
sensitivity and performance (Nicol et al., 2003). Based on the above findings, we suggest that 
long-term BCAA supplementation may not be necessary for the recovery of isometric muscle 
function after muscle damage and that this occurs in parallel to the recovery of CMJ 
performance. Of course, these differences could also be attributed to the application of an 
ostensibly more appropriate statistical technique (Batterham and Hopkins, 2006; Burke, 
2008) compared to previous studies, particularly when the difference between groups is 
small.   
 
Heavy resistance exercise has been shown to induce the release of muscle proteins, such as 
CK, into the blood stream (Kraemer et al., 1993). As anticipated, CK concentration increased 
in the 24-h after muscle damage in both conditions, reflecting disruption of the sarcolemmal 
membrane. However, BCAA supplementation appeared to increase CK compared to placebo 
in the current study, which was not expected. Our findings add to the equivocality of current 
research, with some reporting no change in the CK response after muscle damage (Jackman 
et al., 2010) and others showing an attenuation of the CK response after mixed amino acid or 
BCAA supplementation (Nosaka et al., 2006; Howatson et al., 2012; Kirby et al., 2012). The 
current findings could be attributed to the well-described intra-individual CK response to 
muscle damage, resulting in large standard deviations and random variations in CK values 
across the subsequent days (Clarkson and Ebbeling, 1988). Irrespective of the reasons for 
these findings, the current data question the supposition that CK efflux after muscle damage 
is blunted by BCAA availability. Furthermore, given that soreness was also lower in the 
BCAA group, despite higher CK values, these findings do not support the involvement of 
BCAAs in a proposed mechanism that relies on parallel changes in these measures to explain 
  
a reduction in secondary muscle damage (Howatson et al., 2012). These findings support the 
suggestion that CK might not be a useful single marker of muscle damage (Chrismas et al., 
2013).    
 
This was the first study to test the effect of BCAA supplementation on muscle damage in a 
sample of experienced resistance-trained athletes, who perform habitual hypertrophy training, 
using a mode of exercise that reflects their day-to-day activities. Our findings show that 
muscle damage is caused among athletes of this type and that acute BCAA supplementation, 
prior to and during the recovery period, is capable of accelerating recovery in the 24-48-h 
after a muscle damaging bout of exercise. This is particularly relevant to athletes taking part 
in regular hypertrophy training as programmes of this type necessitate a maximum of 48-h 
between training days. In addition, this is the first study to prescribe and monitor the daily 
diet of resistance-trained participants, thus controlling the total energy and macronutrient 
intake during the BCAA supplementation period. This is an extremely important aspect of the 
current study because, without such measures being taken, the available energy, as well as the 
amount and quality of amino acids being ingested alongside the supplement is unknown. 
Indeed, lack of suitable dietary control has been suggested as a major limitation among 
studies that have investigated the effects of BCAA or protein supplementation on recovery 
from muscle damage (Pasiakos et al., 2015). Our findings, therefore, support studies that have 
reported positive effects of acute BCAA (or isolated leucine or amino acid) supplementation 
on recovery from muscle damage (Kirby et al., 2012) and extend this to diet-controlled, 
experienced resistance-trained athletes.  
 
Whilst the diet of the current participants was under control, it should be stated that, given the 
design of this study which did not include a separate mixed amino acid group, it is unclear 
  
whether the accelerated recovery was due to the BCAA alone mixture or the addition of 
amino acids to the diet. Future studies should extend the current work by including amino 
acid and isolated leucine groups to the experimental design. The isolated leucine group is a 
particularly important part of this suggestion as leucine has the most potent effects on muscle 
protein synthesis via mTor pathways (Philips, 2009), which is not the case for the remaining 
BCAAs, isoleucine and valine (Churchward-Venne et al., 2014). BCAAs, collectively, have 
long-held presumed stimulatory effects on protein synthesis (Blomstrand et al., 2006), which 
might explain their inclusion in recovery drinks. Indeed, this was part of the rationale for the 
current study. However, given the reported competition between leucine, isoleucine and 
valine for cellular transport and subsequent metabolism (Cynober, 2002), it is possible that 
valine and isoleucine inhibited the effects of leucine on muscle protein synthesis and that the 
combination of all three BCAAs is unnecessary or detrimental to muscle recovery (De Bandt 
and Cynober, 2006). 
 
Administration of leucine-rich amino acids has also been shown to reduce the appearance of 
inflammatory cytokines, whilst increasing muscle protein synthesis after eccentric exercise in 
rodents (Kato et al., 2016) and after endurance exercise in athletes (Rowlands et al., 2016). 
Muscle soreness is partly related to local inflammation, which is a necessary part of the 
recovery process that follows acute mechanical damage of the myofibres (Howatson and van 
Someren, 2008). The proposed anti-inflammatory effects of leucine post-exercise might 
explain its capacity to lower muscle soreness. However, there are putative roles for all BCAA 
during the acute inflammatory phase of muscle damage. This is because of the known 
transamination of all BCAA into glutamate and, thus, contribution to the glutamate-glutamine 
pool, which is a known substrate for inflammatory cells (Nicastro et al., 2012). It is, 
therefore, important that future research is designed to examine the effects of isolated BCAA, 
  
most notably leucine, on the inflammatory responses to resistance exercise and associated 
muscle soreness.  
 
Given the unanticipated CK response after the muscle-damaging exercise in the current 
study, it would have been useful to measure other blood markers of muscle damage, such as 
myoglobin, which is known to increase after strenuous exercise (Brancaccio et al., 2010) and 
can be reduced after protein supplementation (Cockburn et al., 2008). This would have 
helped to comprehend the unexpected CK response and provided a more comprehensive 
understanding of the mechanisms by which a BCAA supplement is able to accelerate 
recovery muscle damage, without appearing to alter the level of blood proteins. Indeed, 
replication of this study using different combinations of BCAA dosage would be beneficial, 
given the reports that question the necessity of valine and isoleucine as part of a BCAA 
supplement (De Bandt and Cynober, 2006; Churchward-Venne et al., 2014). Furthermore, 
future studies should investigate the chronic effects of BCAA supplementation on recovery 
from muscle damage as athletes undertaking hypertrophy training will require long term 
recovery strategies and the findings of this study were limited to a 48-h recovery period. 
However, the diet control and supervised supplementation regime that were imposed herein 
to isolate the acute effects of BCAA supplementation would be methodologically challenging 
for future researchers, yet not impossible to achieve. 
 
Conclusion 
Acute oral supplementation of BCAAs at a concentration of 0.087 g/kg body mass was 
sufficient to increase the rate of recovery in isometric strength, CMJ height and perceived 
soreness compared to placebo after a hypertrophy-based training session among resistance-
trained athletes. This means that, based on a 100 kg athlete supplementing twice daily, as 
  
little as 17.2 g/day of BCAAs is necessary to accelerate recovery from hypertrophy training 
sessions. However, further studies are required to understand whether the provision of 
BCAAs, the amino acid content alone or isolated BCAAs are mediating this response. This 
study also highlights the importance of controlling the energy and macronutrient intake of 
participants during research of this type, owing to the potential confounding influence of 
unaccounted dietary food sources on recovery from muscle damage.      
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Figure 1. Changes in isometric strength (% baseline) after muscle damage among the placebo 
and BCAA groups. † = moderate difference between conditions at that time point. 
 
Figure 2. Changes creatine kinase concentration (% baseline) after muscle damage among 
the placebo and BCAA groups. * = large difference between conditions at that time point. 
  
 
Figure 3. Changes counter-movement jump (CMJ) height (% baseline) after muscle damage 
among the placebo and BCAA groups. ¥ = small difference between conditions at that time 
point. 
 
Figure 4. Changes perceived soreness (% baseline) after muscle damage among the placebo 
and BCAA groups. ¥ = small difference between conditions at that time point. 
 
